Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The OVERLOOKED KOL
Summary
In this episode, Tom Caravela hosts Leticia Price and Dawn O'Reilly to discuss the critical role of Advanced Practice Providers (APPs) in the medical field. They explore the educational backgrounds and capabilities of APPs, emphasizing their often underutilized potential as Key Opinion Leaders (KOLs). Strategies for effectively identifying and engaging APPs are shared, along with advice for Physician Assistants (PAs) and Nurse Practitioners (NPs) transitioning to Medical Science Liaison (MSL) roles. The conversation highlights the importance of networking, resource utilization, and effective time management. The episode concludes with insights into the value of APPs in medical progress and territory planning.
My guests this week are Medical Science Liaisons, Dawn O'Reilly and Letitia Price, who discuss the benefits of Medical Science Liaisons engaging with Advanced Practice Providers.
Learn more about…
π What are APPs
π Why should MSLs be calling on APPs
π How can an NP or PA transition to industry
π Why are NPs and PA’s often overlooked
π How can MSLs find success in their territory
Advanced Practice Providers, Medical Science Liaison, Key Opinion Leaders, Physician Assistants, Nurse Practitioners
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary